Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response

References

• Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med.346, 92–98 (2002).
   PubMed Web of Science ®Google Scholar
• Jones JC, Zhen WP, Reed E et al. Gene-specific formation and repair of cisplatin intrastrand adducts and interstrand cross-links in Chinese hamster ovary cells. J. Biol. Chem.266, 7101–7107 (1991).
   PubMed Web of Science ®Google Scholar
• Zeng-Rong N, Paterson J, Alpert L et al. Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy. Cancer Res.55, 4760–4764 (1995).
   PubMed Web of Science ®Google Scholar
• Reed E. ERCC1 and clinical resistance to platinum-based therapy. Clin. Cancer Res.11, 6100–6102 (2005).
   PubMed Web of Science ®Google Scholar
• Sancar A, Reardon JT. Nucleotide excision repair in E. coli and man. Adv. Protein Chem.69, 43–71 (2004).
   PubMedGoogle Scholar
• Hasty P, Campisi J Hoeijmakers J et al. Aging and genome maintenance: lessons from the mouse? Science299, 1355–1359 (2003).
   PubMed Web of Science ®Google Scholar
• Rosell R, Taron M, Barnadas et al. Nucleotide excision repair pathways involved in cisplatin resistance in non-small-cell lung cancer. Cancer Control10, 297–305 (2003).
   PubMedGoogle Scholar
• Li Q, Yu JJ, Mu C et al. Association between the level of ERCC1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res.20, 645–652 (2000).
   PubMed Web of Science ®Google Scholar
• Spitz MR, Wu X, Wang Y et al. Modulation of nucleotide excision repair capacity by XPD polymorphism in lung cancer patients. Cancer Res.61, 1354–1357 (2001).
   PubMed Web of Science ®Google Scholar
• Yu JJ, Lee KB, Mu C et al. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int. J. Oncol.16, 555–560 (2000).
   PubMedGoogle Scholar
• Metzger R, Leichman DG, Danenberg KD et al. ERCC1 levels complement thymidilate sinthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J. Clin. Oncol.16, 309–316 (1998).
   PubMed Web of Science ®Google Scholar
• Shirota Y, Stoehlmacher J, Brabender J et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J. Clin. Oncol.19, 4298–4304 (2001).
   PubMed Web of Science ®Google Scholar
• Dabholkar M, Vionnet J, Bostick-Bruton F et al. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J. Clin. Invest.94, 703–708 (1994).
   PubMed Web of Science ®Google Scholar
• Lord RVN, Brabender J, Gandara D et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res.8, 2286–2291 (2002).
   PubMed Web of Science ®Google Scholar
• Rosell R, Danenberg KD, Alberola V et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res. 10, 1318–1325 (2004).
   PubMed Web of Science ®Google Scholar
• Ceppi P, Volante M, Novello S et al.ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small cell lung cancer treated with cisplatin and gemcitabine. Ann. Oncol.17, 1818–1825 (2006).
   PubMed Web of Science ®Google Scholar
• Bepler G, Kusmartseva I, Sharma S et al. RRM1-modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small cell lung cancer. J. Clin. Oncol.24, 4731–4737 (2006).
   PubMed Web of Science ®Google Scholar
• Rosell R, Felip E, Taron M et al. Gene expression as a predictive marker of outcome in Stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin. Cancer Res.10, 4215s–4219s (2004).
   PubMed Web of Science ®Google Scholar
• Taron M, Rosell R, Felip E et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum. Mol. Genet.13, 2443–2449 (2004).
   PubMed Web of Science ®Google Scholar
• Rosell R, Gandara D, Cobo M et al. Customizing cisplatin-based chemotherapy on quantitative excision repair-cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin. Oncol. (2007) (In Press.)
   Google Scholar
• Simon GR, Sharma S, Cantor A et al. ERCC1 expression is a predictor of survival in resected patients with non-small-cell lung cancer. Chest127, 978–983 (2005).
   PubMed Web of Science ®Google Scholar
• Parker RJ, Eastman A, Bostick-Bruton F et al. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin–DNA lesions and reduced drug accumulation. J. Clin. Invest.87, 772–777 (1991).
   PubMed Web of Science ®Google Scholar
• Ryu JS, Hong YC, Han HS et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer44, 311–316 (2004).
   PubMed Web of Science ®Google Scholar
• Gurubhagavatula S, Liu G, Park S et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J. Clin. Oncol.22, 2594–2601 (2004).
   PubMed Web of Science ®Google Scholar
• Zhou W, Gurubhagavatula S, Liu G et al. Excision repair cross-complementing group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin. Cancer Res.10, 4939–4943 (2004).
   PubMed Web of Science ®Google Scholar
• Suk R, Gurubhagavatula S, Park S et al. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin. Cancer Res.11, 1534–1438 (2005).
   PubMed Web of Science ®Google Scholar
• Isla D, Sarries C, Rosell R et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann. Oncol.15, 1194–1203 (2004).
   PubMed Web of Science ®Google Scholar
• Quintela-Fandino M, Hitt R, Medina Pedro P et al. DNA-repair gene polymorphisms predict favourable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J. Clin. Oncol.24, 4333–4339 (2006).
   PubMed Web of Science ®Google Scholar
• Viguier J, Boige V, Miquel C et al. ERCC1 codon polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin. Cancer Res.17, 6212–6217 (2005).
   Google Scholar
• The International Adjuvant Lung Cancer Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N. Engl. J. Med.350, 351–360 (2004).
   PubMed Web of Science ®Google Scholar
• Olaussen KA, Dunant A, Fouret P et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med.355, 983–991 (2006).
   PubMed Web of Science ®Google Scholar
• Rosell R, Cuello M, Cecere F et al. Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going. Curr. Opin. Oncol.18, 135–143 (2006).
   PubMed Web of Science ®Google Scholar
• Li Q, Gardner K, Zhang L et al. Cisplatin induction of ERCC1 mRNA expression in A2780/CP70 human ovarian cancer cells. J. Biol. Chem.273, 23419–23425 (1998).
   PubMed Web of Science ®Google Scholar
• Yan QW, Reed E, Zhong XS et al. MZF1 possesses a repressively regulatory function in ERCC1 expression. Biochemical Pharmacol.71, 761–771 (2006).
   PubMedGoogle Scholar
• Cecere F, Bria E, Rosell R. DNA repair by ERCC1 in non-small-cell lung cancer. N. Engl. J. Med.355, 2590–2592 (2006).
   PubMedGoogle Scholar
• Zheng Z, Chen T, Li X et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N. Engl. J. Med.356, 771–773 (2007).
   PubMedGoogle Scholar